IntoCell signs MTA with ADC Therapeutics

IntoCell recently announced the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug-linkers developed using their proprietary Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) system and payload modification technology (PMT). ADC […]

Biocytogen signs Antibody Agreement with ADC Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) recently announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. […]